OCCAM Immune Revenue

Biotechnology Research • Manhattan, New York, United States • 1-10 Employees

OCCAM Immune revenue & valuation

Annual revenue	$342,220
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$1,100,000
Total funding	No funding

Key Contact at OCCAM Immune

Erik Wambre

CEO and Co-founder

Company overview

Headquarters	619 W 54th St, New York, NY 10019, US
Website	occam-immune.com
NAICS	541714
Keywords	Biotechnology, Global, Personalized Medicine, Biostatistics, Neurological Disorders, Flow Cytometry, Oncology, Bioinformatics, Proteomics, Genomics, Metabolic Disorders, Clinical Data Management, Infectious Diseases, Histopathology, Immunology, Biologics, Allergy, Translational Science, Immunohistochemistry, Biomarker, Clinical Studies, Immune Monitoring, Immunofluorescence, Tumor Profiling, Fluorescence In Situ Hybridization, Auto-Immune Diseases, Academic Research Organization, Specialty Lab Services, Sample Processing And Storage
Founded	2024
Employees	1-10

OCCAM Immune Email Formats

OCCAM Immune uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@occam-immune.com), used 100% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@occam-immune.com	100%

About OCCAM Immune

OCCAM Immune is a not-for-profit Academic Research Organization (ARO) offering comprehensive immune monitoring services to support pharmaceutical and biotech companies conducting clinical trials. Founded by experts at Mount Sinai Hospital, we specialize in unique biomarker expertise and examining the immune system's response to new therapies across oncology, allergy, infectious diseases, and autoimmune disorders. At the heart of our innovation is Immune Monitoring as a Service (IMaaS), providing access to advanced technologies and standardized immune assays. These include Spectral Flow Cytometry immune phenotyping, Single-cell RNA sequencing, Spatial Transcriptomics, multiplex immunohistochemistry, antigen-specific T cell assays, seromics and antibody profiling, Luminex multiplex assays, Olink assays, and the automated ELLA system—all offered in a cost-effective manner. Additionally, OCCAM Immune ensures comprehensive and streamlined sample processing for patient specimens and biobanking with a Laboratory Information Management System (LIMS). Our approach delivers a detailed examination of the immune system's response to immunotherapy, enriched by expertise in single-cell omics analysis and antigen-specific assays, thus delivering unparalleled insights to our partners.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Employees by Department

OCCAM Immune has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

OCCAM Immune has never raised funding before.

OCCAM Immune Tech Stack

Discover the technologies and tools that power OCCAM Immune's digital infrastructure, from frameworks to analytics platforms.

Jetpack

WordPress plugins

Swiper

JavaScript libraries

jQuery Migrate

JavaScript libraries

Cloudflare

CDN

jQuery

JavaScript libraries

HTTP/3

Miscellaneous

HSTS

Security

PHP

Programming languages

WordPress

Blogs

Yoast SEO

SEO

WordPress.com

PaaS

Nginx

Reverse proxies

Frequently asked questions

OCCAM Immune is located in Manhattan, New York, US.

OCCAM Immune generates an estimated annual revenue of $342,220. This revenue figure reflects the company's market position and business performance in its industry.

OCCAM Immune has an estimated valuation of $1,100,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

OCCAM Immune was founded in 2024, making it 2 years old. The company has established itself as a significant player in its industry over this time.

OCCAM Immune has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at OCCAM Immune

Erik Wambre

CEO and Co-founder

4.8

40,000 users